Bhanji Muna sold $81K of VCYT

Veracyte reported that its Decipher Prostate test can predict which very high-risk nonmetastatic prostate cancer patients may benefit from adding abiraterone to ADT, based on a retrospective Phase III STAMPEDE analysis. The test's evidence base now extends to predicting treatment benefit, not just risk stratification.

Veracyte (VCYT) announced new data showing its Decipher Prostate Genomic Classifier can predict benefit from adding abiraterone to ADT in high-risk prostate cancer patients. The analysis, presented at ESMO 2026, showed 11% 5-year benefit in reducing metastasis for high-risk patients. The findings support broader adoption of Decipher in treatment decisions.

Veracyte (VCYT) announced Medicare coverage for its Prosigna Breast Cancer test, effective August 19, 2026, for eligible patients. The decision marks an early commercialization milestone, according to the company.

Veracyte's Prosigna test for early-stage breast cancer received Medicare coverage, enabling reimbursement for eligible patients. The test helps determine chemotherapy necessity, sparing over two-thirds of high-risk patients, per the OPTIMA trial. Veracyte (VCYT) aims for broader adoption and access.

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the

VERACYTE, INC. (VCYT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veracyte Announces Second Quarter 2026 Financial Results Grew total revenue to $150.3 million and testing revenue to $145.7 million, representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCIS